Loading...
Crinetics Pharmaceuticals, Inc.
CRNX•NASDAQ
Healthcare
Biotechnology
$30.99
$0.58(1.91%)
Crinetics Pharmaceuticals, Inc. (CRNX) Financial Performance & Income Statement Overview
Review Crinetics Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-74.11%
↓ 74.11%
Operating Income Growth
-52.22%
↓ 52.22%
Net Income Growth
-39.10%
↓ 39.10%
Operating Cash Flow Growth
-35.88%
↓ 35.88%
Operating Margin
-49569.74%
↓ 49569.74%
Gross Margin
0.92%
↑ 0.92%
Net Profit Margin
-43191.05%
↓ 43191.05%
ROE
-30.95%
↓ 30.95%
ROIC
-28.89%
↓ 28.89%
Crinetics Pharmaceuticals, Inc. (CRNX) Income Statement & Financial Overview
Review Crinetics Pharmaceuticals, Inc.'s (CRNX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $399000.00 | $640000.00 |
| Cost of Revenue | $0.00 | $0.00 | $753000.00 | $474000.00 |
| Gross Profit | $0.00 | $0.00 | -$354000.00 | $166000.00 |
| Gross Profit Ratio | $0.00 | $0.00 | -$0.89 | $0.26 |
| R&D Expenses | $65.78M | $61.91M | $58.34M | $52.87M |
| SG&A Expenses | $28.18M | $25.89M | $24.84M | $20.83M |
| Operating Expenses | $94.75M | $87.80M | $83.18M | $73.69M |
| Total Costs & Expenses | $94.75M | $87.80M | $83.18M | $74.17M |
| Interest Income | $14.37M | $11.006M | $8.74M | $7.32M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $788000.00 | $770000.00 | $753000.00 | $474000.00 |
| EBITDA | -$93.96M | -$87.03M | -$82.03M | -$73.06M |
| EBITDA Ratio | -$205.59 | -$114.15 | ||
| Operating Income | -$94.75M | -$87.80M | -$82.78M | -$74.17M |
| Operating Income Ratio | -$207.48 | -$115.89 | ||
| Other Income/Expenses (Net) | $14.15M | $10.97M | $8.73M | $6.60M |
| Income Before Tax | -$80.59M | -$76.83M | -$74.06M | -$66.93M |
| Income Before Tax Ratio | -$185.60 | -$104.58 | ||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$80.59M | -$76.83M | -$74.06M | -$66.93M |
| Net Income Ratio | -$185.60 | -$104.58 | ||
| EPS | -$0.88 | -$0.96 | -$0.94 | -$0.93 |
| Diluted EPS | -$0.88 | -$0.96 | -$0.94 | -$0.93 |
| Weighted Avg Shares Outstanding | $91.49M | $80.09M | $79.008M | $72.29M |
| Weighted Avg Shares Outstanding (Diluted) | $91.49M | $80.09M | $79.008M | $72.29M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan